Antisoma says AS1404 offers survival advantage in lung cancer

By Lisa Kerner

Charlotte, N.C., June 7 - Antisoma said in a randomized, phase 2 lung cancer study that patients receiving its vascular disrupting agent AS1404 (DMXAA) plus standard chemotherapy demonstrated increased tumor response rates, longer time to disease progression and enhanced survival compared with patients receiving standard chemotherapy alone.

The company regained all rights to AS1404 from Roche. A phase 3 study of the drug in lung cancer is also planned, according to a company news release.

AS1404 has shown proof of concept in a lung cancer study and has the potential to benefit patients with a variety of cancers, officials said.

Antisoma is conducting an extension study of lung cancer patients being treated with 1,800 mg/m2 AS1404, a higher dose than the 1,200 mg/m2 dose used in the phase 2 trial.

There are more than 1.2 million cases worldwide of lung and bronchial cancer each year, resulting in about 1.1 million deaths, according to the World Health Organization.

Antisoma is a London-based biopharmaceutical company specializing in treatments for cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.